



Atty. Docket No.: 9000/2083

PATENT

TECH CENTER 1600/2900
MAR 26 2003

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Zoghbi et al
Serial No.: 09/884,384
Filed: June 19, 2001
Entitled: Chaperone Suppression of Ataxin-1
Aggregation and Altered Subcellular
Proteasome Localization Imply Protein
Misfolding in SCA1


Examiner: Falk, A.M.
Group Art Unit: 1632
Conf. No.: 5033

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8a

I hereby certify that this correspondence (and any paper or fee referred to as being enclosed) is being deposited with the United States Post Office as First Class Mail on the date indicated below in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231.

Kathleen M. Williams

Name of Person Mailing Paper


Signature of Person Mailing Paper

Commissioner for Patents
Washington, D.C. 20231

AMENDMENT AND RESPONSE TO RESTRICTION REQUIREMENT

Sir:

This is filed in response to the Restriction Requirement mailed December 17, 2002 in the above-noted U.S. patent application. Kindly enter the following amendments and remarks.

In the Claims

Please cancel claims 12, 16 and 19, without prejudice.

Please replace claims 1 and 3 with the following amended claims 1 and 3:

1. (Amended) A method of treating neurodegenerative disease in a mammal comprising the step of introducing a therapeutic effective amount of a chaperone into the neurological system of the mammal.
3. (Amended) The method of claim 1, wherein the introducing step includes directly injecting the chaperone into the mammal.

Please add new claim 25 as follows: